Critical overview and outlook: Pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus

Vaccine

Volumn 21, Issue 32, 2003, Pages 4626-4649

  Hilleman, Maurice R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Hepatitis B; Hepatocarcinoma; Persistent infection; Vaccines

Indexed keywords

ADEFOVIR; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CANCER VACCINE; COMPLEMENTARY DNA; COMPLEMENTARY RNA; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DNA VACCINE; FIALURIDINE; GENHEVAC; HAEMOPHILUS INFLUENZAE VACCINE; HEAT SHOCK PROTEIN; HEPAGEN; HEPATITIS A VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HEPATITIS E ANTIGEN; INACTIVATED VACCINE; INTERFERENCE RIBONUCLEIC ACID; LAMIVUDINE; LIPOPEPTIDE; NUCLEOSIDE; POLIOMYELITIS VACCINE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ANTIGEN; RECOMBINANT DNA; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT RNA; RIBOZYME; THYMOSIN ALPHA1; TUMOR PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AUTOIMMUNITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG APPROVAL; EARLY DIAGNOSIS; GENE DELIVERY SYSTEM; GENE REPRESSION; GENE SILENCING; GRAFT INFECTION; HEPATITIS B; HEPATITIS B VIRUS; HOST PARASITE INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; INFECTION PREVENTION; LACTIC ACIDOSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NEPHROTOXICITY; NONHUMAN; PASSIVE IMMUNIZATION; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; VIRUS GENE; VIRUS PATHOGENESIS;

EID: 0142227000     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00529-2     Document Type: Review

References (215)

1. Hilleman M.R. Overview of the pathogenesis, prophylaxis, and therapeusis of viral hepatitis B, with focus on reduction to practical applications. Vaccine. 19:2001;1837-1848.
2. Ganem D, Schneider RJ. Hepadnaviridae: viruses and their replication. In: Knipe DM, Howley PM, editors. Fields virology. 4th ed. Philadelphia: Lippincott, Williams and Wilkins; 2001, chapter 86. p. 2923-69.
3. Hollinger FB, Liang TJ. Hepatitis B virus. In: Knipe DM, Howley PM, editors. Fields virology. 4th ed. Philadelphia: Lippincott, Williams and Wilkins; 2001, chapter 87. p. 2971-3036.
4. Heilman C, McInnes P, Landry S, editors. The Jordan Report. Accelerated Development of Vaccines 2002. Bethesda (MD): National Institute of Allergy and Infectious Diseases, National Institutes of Health; 2002. 305 p.
5. Atkinson W, Wolfe C, Humiston S, Nelson R, editors. Epidemiology and prevention of vaccine-preventable diseases. 6th ed. Atlanta (GA): Centers for Disease Control and Prevention, US Department of Health and Human Services; 2002, 276 p., appendices.
6. Pumpens P., Grens E., Nassal M. Molecular epidemiology and immunology of hepatitis B virus infection - an update. Intervirology. 45:2002;218-232.
7. Xu D.-Z., Yan Y.-P., Choi B.C.K., Xu J.-Q., Men K., Zhang J.-X.et al. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J. Med. Virol. 67:2002;20-26.
8. Parkin D.M., Pisani P., Ferlay J. Estimates of the worldwide incidence of 24 major cancers in 1990. Int. J. Cancer. 80:1999;827-841.
9. Schlicht H.-J., Schaller H. The secretory core protein of human hepatitis B virus is expressed on the cell surface. J. Virol. 63:1989;5399-5404.
10. Milich D.R., Jones J.R., Hughes J.L., Price J., Raney A.K., McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc. Natl. Acad. Sci. U.S.A. 87:1990;6599-6603.
11. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J. Clin. Virol. 25:2002;97-106.
12. Kidd-Ljunggren K., Miyakawa Y., Kidd A.H. Genetic variability in hepatitis B viruses. J. Gen. Virol. 83:2002;1267-1280.
13. Kao J.-H. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J. Gastroenterol. Hepatol. 17:2002;643-650.
14. Chan H.L.-Y., Wong M.L., Hui A.Y., Hung L.C.-T., Chan F.K.-L., Sung J.J.-Y. Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigen-positive patients. J. Clin. Microbiol. 41:2003;1277-1279.
15. Jung M.-C., Pape G.R. Immunology of hepatitis B infection. Lancet Infect. Dis. 2:2002;43-50.
16. Walsh K., Alexander G.J.M. Update on chronic viral hepatitis. Postgrad. Med. J. 77:2001;498-505.
17. Maini M.K., Boni C., Lee C.K., Larrubia J.R., Reignat S., Ogg G.S.et al. The role of virus-specific CD8+ cells in liver damage and viral control during persistent hepatitis B virus infection. J. Exp. Med. 191:2000;1269-1280.
18. Rehermann B. Immune responses to hepatitis B virus infection. Semin. Liver Dis. 23:2003;21-37.
19. Tai P.-C., Suk F.-M., Gerlich W.H., Neurath A.R., Shih C. Hypermodification and immune escape of an internally deleted middle-envelope (M) protein of frequent and predominant hepatitis B virus variants. Virology. 292:2002;44-58.
20. Favoreel H.W., Van deWalle G.R., Nauwynck H.J., Pensaert M.B. Virus complement evasion strategies. J. Gen. Virol. 84:2003;1-15.
21. Alcami A. Viral mimicry of cytokines. Nat. Rev. Immunol. 3:2003;36-50.
22. Vanlandschoot P., Leroux-Roels G. Viral apoptotic mimicry: an immune evasion strategy developed by the hepatitis B virus? Trends Immunol. 24:2003;144-147.
23. Michel M.-L. Towards immunotherapy for chronic hepatitis B virus infections. Vaccine. 20:2002;A83-A88.
24. Kakimi K., Guidotti L.G., Koezuka Y., Chisari F.V. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J. Exp. Med. 192:2000;921-930.
25. Guidotti L.G. The role of cytotoxic T cells and cytokines in the control of hepatitis B virus infection. Vaccine. 20:2002;A80-A82.
26. Akbar S.M.F., Horiike N., Onji M., Hino O. Dendritic cells and chronic hepatitis virus carriers. Intervirology. 44:2001;199-208.
27. Yalcin K., Degertekin H., Yildiz F., Celik Y. Markers of disease activity in chronic hepatitis B virus infection. Clin. Invest. Med. 26:2003;27-34.
28. Brunetto M.R., Rodriguez U.A., Bonino F. Hepatitis B virus mutants. Intervirology. 42:1999;69-80.
29. Rehermann B., Ferrari C., Pasquinelli C., Chisari F.V. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat. Med. 2:1996;1104-1108.
30. Minuk G.Y. Hepatitis B viral mutants and their relevance to the Canadian health care system. Can. J. Gastroenterol. 16:2002;45-54.
31. Chisari F.V. Hepatitis B virus in transgenic mice: insights into the virus and the disease. Hepatology. 22:1995;1316-1325.
32. Guidotti L.G., Rochford R., Chung J., Shapiro M., Purcell R., Chisari F.V. Viral clearance without destruction of infected cells during acute HBV infection. Science. 284:1999;825-829.
33. Chisari F.V. Viruses. Am. J. Pathol. 156:2000;1118-1132.
34. Uprichard S.L., Wieland S.F., Althage A., Chasari F.V. Transcriptional and posttranscriptional control of hepatitis B virus gene expression. Proc. Natl. Acad. Sci. U.S.A. 100:2003;1310-1315.
35. Thimme R., Wieland S., Steiger C., Ghrayeh J., Reimann K.A., Purcell R.H. CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J. Virol. 77:2003;68-76.
36. Hofseth LJ, Hussain SP, Wogan GN, Harris CC. Serial review nitric oxide in cancer biology and treatment. In: Wink DA, Mitchell JB, editors. Free radical biology & medicine, vol. 34. New York: Elsevier; 2003. p. 955-68.
37. b mice in utero. Virology. 243:1998;45-53.
38. Wang J.-S., Zhu Q.-R. Infection of the fetus with hepatitis B e antigen via the placenta. Lancet. 355:2000;989.
39. Milich D.R., Chen M.K., Hughes J.L., Jones J.E. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J. Immunol. 160:1998;2013-2021.
40. Liang T.J., Ghany M. Hepatitis B e antigen - the dangerous endgame of hepatitis B. N. Engl. J. Med. 347:2002;208-210.
41. Tsai S.L., Chen P.J., Lai M.Y., Yang P.M., Sung J.L., Huang J.H.et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. J. Clin. Invest. 89:1992;87-96.
42. Mast E.E., Alter M.J. Epidemiology of viral hepatitis: an overview. Virology. 4:1993;273-283.
43. Purcell R.H. Hepatitis viruses: changing patterns of human disease. Proc. Natl. Acad. Sci. U.S.A. 91:1994;2401-2406.
44. Blumberg B.S., Gerstley B.J.S., Hungerford D.A., London W.T., Sutnich A.I. A serum antigen (Australia antigen) in Down's syndrome, leukemia, hepatitis. Ann. Int. Med. 66:1967;924-931.
45. Hilleman MR, Plasma derived hepatitis B vaccine - a breakthrough in preventive medicine. In: Ellis R, editor. Hepatitis B vaccines in clinical practice. New York: Marcel Dekker; 1992. p. 17-39.
46. Buynak E.B., Roehm R.R., Tytell A.A., Bertland A.U., Lampson G.P., Hilleman M.R. Vaccine against human hepatitis B. J. Am. Med. Assoc. 235:1976;2832-2834.
47. Douglas R.G. Jr. The heritage of hepatitis B vaccine. J. Am. Med. Assoc. 276:1996;1796-1798.
48. Hilleman M.R., McAleer W.J., Buynak E.B., McLena A.A. The preparation and safety of hepatitis B vaccine. J. Infect. 7(Suppl 1):1983;3-8.
49. Szmuness W., Stevens C.E., Zang E.A., Harley E.J., Keller A. A controlled clinical trial of the efficacy of hepatitis B vaccine (Heptavax B): a final report. Hepatology. 1:1981;377-385.
50. Francis D.P., Hadler S.C., Thompson S.E., Maynard J.E., Ostrow D.G., Altman N. The prevention of hepatitis B with vaccine. Report of the Centers for Disease Control Multi-Center Efficacy Trial Among Homosexual Men. Ann. Int. Med. 97:1982;362-366.
51. Esser M.T., Marchese R.D., Kierstead L.S., Tussey L.G., Wang F., Chirmule N.et al. Memory T cells and vaccines. Vaccine. 21:2003;419-430.
52. Valenzuela P., Medina A., Rutter W.J., Ammerer G., Hall B.D. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature. 298:1982;347-350.
53. McAleer W.J., Buynak E.B., Maigetter R.Z., Wampler D.E., Miller W.J., Hilleman M.R. Human hepatitis B vaccine from recombinant yeast. Nature. 307:1984;178-180.
54. Hilleman M.R. Yeast recombinant hepatitis B vaccine. Infection. 15:1987;2-6.
55. Hilleman MR. Three decades of hepatitis vaccinology in historic perspective. A paradigm of successful pursuits. In: Plotkin S, Fantini B, editors. Vaccinia, vaccination and vaccinology: Jenner, Pasteur and their successors. Paris: Elsevier; 1996. p. 199-209.
56. Hilleman MR. Immunology, vaccinology, and pathogenesis of hepatitis B. In: Koprowski H, Oldstone MBA, editors. Microbe hunters. Then and now. Bloomington: Medi Ed Press; 1996. p. 221-34.
57. Vryheid R.E., Kane M.A., Muller N., Schatz G.C., Bezabeh S. Infant and adolescent hepatitis B immunization up to 1999: a global overview. Vaccine. 19:2001;1026-1037.
58. World Health Organization. Expanded programme on immunization. Global advisory group. Part 1. Wkly Epidemiol Rec 1992;3:11-6.
59. Nossal G.J.V. The global alliance for vaccines and immunization - a millennial challenge. Nat. Immunol. 1:2000;5-8.
60. Kane M.A., Brooks A. New immunization initiatives toward the global control of hepatitis B. Curr. Opin. Infect. Dis. 15:2002;465-469.
61. Yusuf H., Daniels D., Mast E.E., Coronado V. Hepatitis B vaccination coverage among United States children. Pediatr. Infect. Dis. J. 20:2001;S30-S33.
62. Van Damme P., Vorsters A. Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001. J. Med. Virol. 67:2002;433-439.
63. Goldstein S.T., Fiore A.E. Toward the global elimination of hepatitis B virus transmission. J. Pediatr. 139:2001;343-345.
64. Schmidt R.M., Middleman A.B. The importance of hepatitis B vaccination among adolescents. J. Adolesc. Health. 29:2001;217-222.
65. McMahon BJ, Wainwright RB. Protective efficacy of hepatitis B vaccines in infants, children and adults. In: Ellis RW, editors. Hepatitis B vaccines in clinical practice. New York: Marcel Dekker; 1993. p. 243-61.
66. Kao J.-H., Chen D.-S. Global control of hepatitis B virus infection. Lancet Infect. Dis. 2:2002;395-403.
67. Desombere I., Willems A., Leroux-Roels G. Response to hepatitis B vaccine: multiple HLA genes are involved. Tissue Antigens. 51:1998;593-604.
68. Singh M., O'Hagan D.T. Recent advances in vaccine adjuvants. Pharm. Res. 19:2002;715-728.
69. Rendi-Wagner P., Wiedermann G., Stemberger H., Kollaritsch H. New vaccination strategies for low- and non-responders to hepatitis B vaccine. Wien. Klin. Wochenschr. 114:2002;175-180.
70. Kim M.-J., Nafziger A.N., Harro C.D., Keyserling H.L., Ramsey K.M., Drusano G.L.et al. Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response. Vaccine. 21:2003;1174-1179.
71. Banatvala J.E., Van Damme P. Hepatitis B vaccine - do we need boosters? J. Viral. Hepat. 10:2003;1-6.
72. Young B.W.Y., Lee S.S., Lim W.L., Yeoh E.K. The long-term efficacy of plasma-derived hepatitis B vaccine in babies born to carrier mothers. J. Viral. Hepat. 10:2003;23-30.
73. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000;355:561-5.
74. Lampson G.P., Tytell A.A., Field A.K., Nemes M.M., Hilleman M.R. Inducers of interferon and host resistance. I. Double-stranded RNA from extracts of Penicillium funiculosum. Proc. Natl. Acad. Sci. U.S.A. 58:1967;782-789.
75. Harrison TJ, Zuckerman AJ. Variant hepatitis B and D viruses. In: Ellis RW, editor. Hepatitis B vaccines in clinical practice. New York: Marcel Dekker; 1993, chapter 18. p. 337-49.
76. He C., Nomura F., Itoga S., Isobe K., Nakai T. Prevalence of vaccine-induced escape mutants of hepatitis B virus in the adult population of China: a prospective study in 176 restaurant employees. J. Gastroenterol. Hepatol. 16:2001;1373-1377.
77. Carman W.F., Zanetti A.R., Karayiannis P., Waters J., Manzillo G., Tanzi E.et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet. 336:1990;325-329.
78. Howard CR, Stirk HJ, Brown SE, Steward MW. Towards the development of synthetic hepatitis B vaccines. In: Zuckerman AJ, editors. Viral hepatitis and liver disease. New York: Alan R. Liss; 1988. p. 1094-101.
79. Wallace L.A., Carman W.F. Surface gene variation of HBV: scientific and medical relevance. Viral Hepat. Rev. 3:1997;5-16.
80. Protzer-Knolle U., Naumann U., Bartenschlager R., Berg T., Hoff U., zum Buschenfelde K.-H.M. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology. 27:1998;254-263.
81. Ogata N., Zanetti A.R., Yu M., Miller R.H., Purcell R.H. Infectivity and pathogenicity in chimpanzees of a surface gene mutant of hepatitis B virus that emerged in a vaccinated infant. J. Infect. Dis. 175:1997;511-523.
82. Ogata N., Cote P.J., Zanetti A.R., Miller R.H., Shapiro M., Gerin J.et al. Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus. Hepatology. 30:1999;779-786.
83. Purcell R.H. Hepatitis B virus mutants and efficacy of vaccination. Lancet. 356:2000;769.
84. Dupuis M., McDonald D.M., Ott G. Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. Vaccine. 18:2000;434-439.
85. Hilleman MR. Overview of vaccinology in historic and future perspective: the whence and whither of a dynamic science with complex dimensions. In: Ertl HCJ, editor. DNA vaccines. New York: Plenum Press; 2003. p. 1-38.
86. Cichutek K. DNA vaccines: development, standardization and regulation. Intervirology. 43:2000;331-338.
87. Fuchs F. Quality control of biotechnology-derived vaccines: technical and regulatory considerations. Biochimie. 84:2002;1173-1179.
88. Lieberman J.M. Combination vaccines in pediatric practice. Am. J. Manage. Care. 9(Suppl 1):2003;S3-S5.
89. FitzSimons D., Francois G., Emiroǧlu N., Van Damme P. Combined hepatitis B vaccines. Vaccine. 21:2003;1310-1316.
90. McNeil Jr DG. Combined vaccine gets FDA approval. New York Times, December 17, 2002.
91. Rich J.D., Ching C.G., Lally M.A., Gaitanis M.M., Schwartzapfel B., Charuvastra A.et al. A review of the case for hepatitis B vaccination of high-risk adults. Am. J. Med. 114:2003;316-318.
92. Chen R.Y.M., Desmond P.V., Locarnini S.A. Emerging therapies of hepatitis B and C. J. Gastroenterol. Hepatol. 17(Suppl):2002;S471-S481.
93. Nguyen M.H., Wright T.L. Therapeutic advances in the management of hepatitis B and hepatitis C. Curr. Opin. Infect. Dis. 14:2001;593-601.
94. Conjeevaram H.S., Lok A.S.-F. Management of chronic hepatitis B. J. Hepatol. 38(Suppl):2003;S90-S103.
95. Wai C.T., Lok A.S.F. Treatment of hepatitis B. Gastroenterology. 37:2002;771-778.
96. Jain A.B., Fung J.J. Advances in hepatitis B virus infection. Transpl. Proc. 35:2003;342-344.
97. Estaban R. Management of chronic hepatitis B: an overview. Semin. Liver Dis. 22(Suppl 1):2002;1-6.
98. Lok A.S., Healthcote J., Hoofnagle J.H. Management of hepatitis B 2000: summary of a workshop. Gastroenterology. 120:2001;1828-1853.
99. Pramoolsinsup C. Management of viral hepatitis B. J. Gastroenterol. Heptatol. 17(Suppl):2002;S125-S145.
100. Boni C., Bertoletti A., Penna A., Cavalli A., Pilli M., Urbani S. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J. Clin. Invest. 102:1998;968-975.
101. Sprengers D., Janssen H.L.A., Kwekkeboom J., Niesters H.G.M., deMan R.A., Schalm S.W. In vivo immunization following virus suppression: a novel approach for inducing immune control in chronic hepatitis B. J. Viral. Hepat. 10:2003;7-9.
102. McKenzie R., Fried M.W., Sallie R., Conjeevaram H., DiBisceglie A.M., Park Y.et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N. Engl. J. Med. 333:1995;1099-1105.
103. Villamil F.G. Hepatitis B: progress in the last 15 years. Liver Transpl. 8(Suppl 1):2002;S59-S66.
104. Ben-Ari M.E., Tur-Kaspa R. Experience with lamivudine therapy for hepatitis B virus infection before and after liver transplantation, and review of the literature. J. Inter. Med. 253:2003;544-552.
105. Lau G.K.K., Lok A.S.F., Liang R.H.S., Lai C.L., Chiu E.K.W., Lau Y.L.et al. Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology. 25:1997;1497-1501.
106. Lindemann M., Barsegian V., Runde V., Fiedler M., Heermann K.-H., Schaefer U.W.et al. Transfer of humoral and cellular hepatitis B immunity by allogeneic hematopoietic cell transplantation. Transplant. 75:2003;833-838.
107. Blum HE. Gene therapy of viral hepatitis. In: Tsuji T, Higashi T, Zeniya M, Meyer zum Büschenfelde KH, editors. Molecular biology and immunology in hepatology. New York: Elsevier Science; 2002, chapter 8. p. 97-109.
108. Gold L., Brody E., Heilig J., Singer B. One, two infinity: genomes filled with aptamers. Chem. Biol. 9:2002;1259-1264.
109. Kurreck J. Antisense technologies. Eur. J. Biochem. 270:2003;1628-1644.
110. Cho-Chung Y.S. Antisense DNAs as targeted genetic medicine to treat cancer. Arch. Pharm. Res. 26:2003;183-191.
111. Spangenberg H.C., Wands J.R. Ribozymes and hepatitis B virus. J. Gastroentrol. Hepatol. 16:2001;1084-1085.
112. Scaglioni P., Melegari M., Takahashi M., Chowdhury R., Wands J. Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology. 24:1996;1010-1017.
113. Feng Y., Kong Y.-Y., Wang Y., Qi G.-R. Intracellular inhibition of the replication of hepatitis B virus by hammerhead ribozymes. J. Gastroenterol. Hepatol. 16:2001;1125-1130.
114. von Weizsacker F., Wieland S., Kock J., Offensperger W.-B., Offensperger S., Moradpour D.et al. Gene therapy for chromic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants. Hepatology. 26:1997;251-255.
115. Butz K., Denk C., Fitscher B., Crnkovic-Mertens I., Ullmann A., Schröder C.H.et al. Peptide aptamers targeting the hepatitis B core protein: a new class of molecules with antiviral activity. Oncogene. 20:2001;6579-6586.
116. Zamore P.D. Ancient pathways programmed by small RNAs. Science. 296:2002;1265-1269.
117. Ramaswamy G., Slack F.J. siRNA: a guide for RNA silencing. Chem. Biol. 9:2002;1053-1057.
118. Cottrell T.R., Doering T.L. Silence of the strands: RNA interference in eukaryotic pathogens. Trends Microbiol. 11:2003;37-43.
119. Xia H., Mao Q., Paulson H.L., Davidson B.L. siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol. 20:2002;1006-1010.
120. Kitabwalla M., Ruprecht R.M. RNA interference - a new weapon against HIV and beyond. N. Engl. J. Med. 347:2002;1364-1367.
121. Cullen B.R. RNA interference: antiviral defense and genetic tool. Nat. Immunol. 3:2002;597-599.
122. McManus M.T., Sharp P.A. Gene silencing in mammals by small interfering RNAs. Nat. Rev. Genet. 3:2002;737-747.
123. Brummelkamp T.R., Bernards R., Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 296:2002;550-553.
124. Carmichael G.G. Antisense starts making more sense. Nat. Biotechnol. 21:2003;371-372.
125. Turker M.S. Gene silencing in mammalian cells and the spread of DNA methylation. Oncogene. 21:2002;5388-5393.
126. Verma M. Viral genes and methylation. Ann. N.Y. Acad. Sci. 983:2003;170-180.
127. Ge Q., McManus M.T., Nguyen T., Shen C.-H., Sharp P.A., Eisen H.N.et al. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc. Natl. Acad. Sci. U.S.A. 100:2003;2718-2723.
128. Randall G., Grakoui A., Rice C.M. Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc. Natl. Acad. Sci. U.S.A. 100:2003;235-240.
129. Coburn G.A., Cullen B.R. Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J. Virol. 76:2002;9225-9231.
130. Malhotra P., Dasaradhi P.V.N., Kumar A., Mohmmed A., Agrawal N., Bhatnagar R.K. Double-stranded RNA-mediated gene silencing of cysteine proteases (falcipain-1 and -2) of Plasmodium falciparum. Mol. Microbiol. 45:2002;1245-1254.
131. McCaffrey A.P., Nakai H., Pandey K., Huang Z., Salazar F.H., Xu H.et al. Inhibition of hepatitis B in mice by RNA interference. Nat. Biotechnol. 21:2003;639-644.
132. Shlomai A., Shaul Y. Inhibition of hepatitis B virus expression and replication of RNA interference. Hepatology. 37:2003;764-770.
133. Hilleman M.R. Personal historical chronicle of six decades of basic and applied research in virology, immunology, and vaccinology. Immunol. Rev. 170:1999;7-27.
134. Field A.K., Lampson G.P., Tytell A.A., Nemes M.M., Hilleman M.R. Inducers of interferon and host resistance. IV. Double-stranded replicative form RNA (MS2-RF-RNA) from E. coli infected with MS2 coliphage. Proc. Natl. Acad. Sci. U.S.A. 58:1967;2102-2108.
135. Tytell A.A., Lampson G.P., Field A.K., Hilleman M.R. Inducers of interferon and host resistance. III. Double-stranded RNA from reovirus type 3 virions (Reo 3-RNA). Proc. Natl. Acad. Sci. U.S.A. 58:1967;1719-1722.
136. Field A.K., Tytell A.A., Lampson G.P., Hilleman M.R. Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes. Proc. Natl. Acad. Sci. U.S.A. 58:1967;1004-1010.
137. Field A.K., Tytell A.A., Lampson G.P., Hilleman M.R. Inducers of interferon and host resistance. IV. In vitro studies. Proc. Natl. Acad. Sci. U.S.A. 61:1968;340-346.
138. Hilleman M.R. Double-stranded RNA's (Poly I:C) in the prevention of viral interferon. Arch. Intern. Med. 126:1970;109-124.
139. Hilleman MR, Lampson GP, Tytell AA, Field AK, Nemes MM, Krakoff IH, et al. Double-stranded RNA in relation to interferon induction and adjuvant activity. In: Beers RF, Braun W, editors. Biological effects of polynucleotides. New York: Springer-Verlag; 1971. p. 27-44.
140. Field A.K., Young C.W., Krakoff I.H., Tytell A.A., Lampson G.P., Nemes M.M.et al. Induction of interferon in human subjects by Poly I:C. Proc. Soc. Exp. Biol. Med. 136:1971;1180-1186.
141. Dienstag J.L., Stevens C.E., Bhan A.K., Szmuness W. Hepatitis B vaccine administered to chronic carriers of hepatitis B surface antigen. Ann. Intern. Med. 96:1982;575-579.
142. Dikici B., Bosnak M., Ucmak H., Dagli A., Ece A., Haspolat K. Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection. Hepatology. 18:2003;218-222.
143. Senturk H., Tabak F., Akdogan M., Erdem L., Mert A., Ozaros R.et al. Therapeutic vaccination in chronic hepatitis B. J. Gastroenterol. Hepatol. 17:2002;72-76.
144. Couillin I., Pol S., Mancini M., Driss F., Brechot C., Tiollais P.et al. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J. Infect. Dis. 180:1999;15-26.
145. Livingston B.D., Alexander J., Crimi C., Oseroff C., Celis E., Daly K.et al. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J. Immunol. 162:1999;3088-3095.
146. Heathcote J., McHutchison J., Lee S., Tong M., Benner K., Minuk G.et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. Hepatology. 30:1999;531-536.
147. Vitiello A., Ishioka G., Grey H.M., Rose R., Farness P., LaFond R.et al. Development of lipopeptide-based therapeutic vaccine to treat chronic HBV infection Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest. 95:1995;341-349.
148. Srivastava I.K., Liu M.A. Gene vaccines. Ann. Intern. Med. 138:2003;550-559.
149. Michel M.-L., Loriat D. DNA vaccines for prophylactic or therapeutic immunization against hepatitis B. Intervirology. 44:2001;78-87.
150. Davis H.L., McCluskie M.J., Gerin J.L., Purcell R.H. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc. Natl. Acad. Sci. U.S.A. 93:1996;7213-7218.
151. Prince A.M., Whalen R., Brotman B. Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus. Vaccine. 15:1997;916-919.
152. Pancholi P., Lee D.-H., Liu Q., Tackney C., Taylor P., Perkus M.et al. DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology. 33:2001;448-454.
153. Sällberg M., Hughes J., Javadian A., Ronlov G., Hultgren C., Townsend K.et al. Genetic immunization of chimpanzees chronically infected with hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B core antigen. Hum. Gene Ther. 9:1998;1719-1729.
154. Hervas-Stubbs S., Lasarte J.J., Sarobe P., Prieto J., Cullen J., Roggendorf M.et al. Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection. J. Hepatol. 27:1997;726-737.
155. Liu M.A. DNA vaccines: a review. J. Intern. Med. 253:2003;402-410.
156. Boni C., Penna A., Ogg G.S., Bertoletti A., Pilli M., Cavallo C.et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology. 33:2001;963-971.
157. Lainé S., Salhi S., Rossignol J.-M. Overexpression and purification of the hepatitis B e antigen precursor. J. Virol. Methods. 103:2002;67-74.
158. Zhou F., Sui L., Luo K., Hou J. Cloning and expression and purification of hepatitis B e-antigen precursor on Escherichia coli. Chin. Med. J. 115:2002;722-725.
159. Fong Y, Kemeny N, Lawrence TS. Cancer of the liver and biliary tree. In: DeVita Jr VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. 6th ed. Philadelphia: Lippincott, Williams and Wilkins; 2001. p. 1162-203.
160. Kensler T.W., Qian G.-S., Chen J.-G., Groopman J.D. Translational strategies for cancer prevention in liver. Nat. Rev. Cancer. 3:2003;321-329.
161. Sung J-L, Chen D-S, Lee C-Y, Hsu H-M, Low K-J. Prevention of hepatocellular carcinoma. In: Ellis RW, editors. Hepatitis B vaccines in clinical practice. New York: Marcel Dekker; 1993. p. 263-78.
162. Geissler M, Gesien A, Wands JR. Molecular mechanisms of hepatocarcinogenesis. In: Okuda K, Tabor E, editors. Liver cancer. New York: Churchill Livingstone; 1997, chapter 6. p. 59-88.
163. Wogan GN. Aflatoxin exposure as a risk factor in the etiology of hepatocellular carcinoma. In: Okuda K, Tabor E, editors. Liver cancer. New York: Churchill Livingstone; 1997, chapter 5. p. 51-8.
164. Thorgeirsson S.S., Grisham J.W. Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet. 31:2002;339-346.
165. Chen P-J, Chen D-S. Hepatitis B virus and hepatocellular carcinoma. In: Okuda K, Tabor E, editors. Liver cancer. New York: Churchill Livingstone; 1997, chapter 3. p. 29-37.
166. Koike K. Transgenic mouse models for viral hepatitis: the role of hepatitis viruses in hepatocarcinogenesis. In: Tsuji T, Higashi T, Zeniya M, Meyer zum Büschenfelde K-H, editors. Molecular biology and immunology in hepatology. Amsterdam: Elsevier; 2002. p. 85-96.
167. Hwang G.-Y., Huang C.-J., Lin C.-Y., Wu C.-C. Dominant mutations of hepatitis B virus variants in hepatoma accumulate in B-cell and T-cell epitopes of the HBx antigen. Virus Res. 92:2003;157-164.
168. Hino O., Kajino K., Umeda T., Arakawa Y. Understanding the hypercarcinogenic state in chronic hepatitis: a clue to the prevention of human hepatocellular carcinoma. J. Gastroenterol. 37:2002;883-887.
169. Goldman L, Bennett JC, editors. Cecil textbook of medicine. 21st ed. Philadelphia: Saunders; 2000. 2223 p.
170. Befeler A, DiBisceglie AM, Treatment of hepatocellular carcinoma. In: Tabor E, editors. Viruses and liver cancer. Amsterdam: Elsevier. p. 161-72.
171. Heyward W.L., Lanier A.P., McMahon B.J., Fitzgerald M.A., Kilkenny S., Paprocki T.R. Early detection of primary hepatocellular carcinoma. Screening for primary hepatocellular carcinoma among persons infected with hepatitis B virus. J. Am. Med. Assoc. 254:1985;3052-3054.
172. Yao F.Y. Dramatic reduction of the α-fetoprotein level after Lamivudine treatment of patients with chronic hepatitis B virus infection and cirrhosis. J. Clin. Gastroenterol. 36:2003;440-442.
173. Restifo NP, Sznol M, Overwijk WW, Therapeutic cancer vaccines. In: DeVita Jr VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. 6th ed. Philadelphia: Lippincott, Williams and Wilkins; 2001, chapter 63, section 2. p. 3195-217.
174. Whelan M., Whelan J., Russell N., Dalgleish A. Cancer immunotherapy: an embarrassment of riches? Drug Discov. Today. 8:2003;253-258.
175. Dermime S., Armstrong A., Hawkins R.E., Stern P.L. Cancer vaccines and immunotherapy. Br. Med. Bull. 62:2002;149-162.
176. Fabre J.W. The allogeneic response and tumor immunity. Nat. Med. 7:2001;649-652.
177. Vermorken J.B., Van Tendeloo V.F.I. Dendritic cell therapy of cancer: can it fulfill its promise? Expert Rev. Anticancer Ther. 3:2003;1-3.
178. Sabel M.S., Sondak V.K. Tumor vaccines. A role in preventing recurrence in melanoma? Am. J. Clin. Dermatol. 3:2002;609-616.
179. Jerne N.K. Towards a network theory of the immune system. Ann. Immunol. (Paris). 125:1974;373-389.
180. Srivastava P.K. Immunotherapy of human cancer: lessons from mice. Nat. Immunol. 1:2000;363-366.
181. Srivastava P. Roles of heat shock proteins innate and adaptive immunity. Nat. Rev. Immuunol. 2:2002;185-194.
182. Basu S., Binder R.J., Suto R., Anderson K.M., Srivastava P.K. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway. Int. Immunol. 12:2000;1539-1546.
183. Binder R.J., Han D.K., Srivastava P.K. CD91: a receptor for heat shock protein gp96. Nat. Immunol. 1:2000;151-155.
184. Basu S., Binder R.J., Ramalingam T., Srivastava P.K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity. 14:2001;303-313.
185. Somersan S., Larsson M., Fonteneau J.F., Basu S., Srivastava P.K., Bhardwaj N. Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J. Immunol. 167:2001;4844-4852.
186. Belli F., Testori A., Rivoltini L., Maio M., Andreola G., Sertoli M.R.et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol. 20:2002;4169-4180.
187. Goldman B. Turning up the heat on cancer. A conversation with Pramod Srivastava, Ph.D. Biopeople. PJB Publications Ltd.; 2003. 3 p.
188. Gallucci S., Lolkema M., Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5:1999;1249-1255.
189. Goldman B. Cancer vaccines: finding the best way to train the immune system. J. Nat. Cancer Inst. 94:2002;1523-1526.
190. Masood S., Mui M.M. Prognostic and predictive value of HER2/neu oncogene in breast cancer. Microsc. Res. Technol. 59:2002;102-108.
191. Rosenberg S.A., Yanelli J.R., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S. Treatment of patients with metastatic melanoma with antologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86:1994;1159-1166.
192. Waldmann T.A. Immunotherapy: past, present and future. Nat. Med. 9:2003;269-277.
193. Ochsenbein A.F. Principles of tumor immunosurveillance and implications for immunotherapy. Cancer Gene Ther. 9:2002;1043-1055.
194. Labeur M.S., Roters B., Pars B., Mehling A., Luger T.A., Schwarz T. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J. Immunol. 162:1999;168-175.
195. Karayiannis P. Hepatitis B virus: old, new and future approaches to antiviral treatment. J. Antimicrob. Chemother. 51:2003;761-785.
196. Chiocca E.A. Oncolytic viruses. Nat. Rev. Cancer. 2:2002;938-950.
197. Ring C.J.A. Cytolytic viruses as potential anti-cancer agents. J. Gen. Virol. 83:2002;491-502.
198. Folkman J. Angiogenesis and apoptosis. Semin. Cancer Biol. 13:2003;159-167.
199. Kaban K., Herbst R.S. Angiogenesis as a target for cancer therapy. Hematol. Oncol. Clin. N. Am. 16:2002;1125-1171.
200. Peng Y., Zhang Q., Nagasawa H., Okayasu R., Liber H.L., Bedford J.S. Silencing expression of the catalytic subunit of DNA-dependent protein kinase by small interfering RNA sensitizes human cells for radiation-induced chromosome damage, cell killing, and mutation. Cancer Res. 62:2002;6400-6404.
201. Borkhardt A. Blocking oncogenes in malignant cells by RNA interference - new hope for a highly specific cancer treatment? Cancer Cell. 2:2002;167-168.
202. Shuey D.J., McCallus D.E., Giordano T. RNAi: gene-silencing in therapeutic intervention. Drug Discov. Today. 7:2002;1040-1046.
203. Frankish H. Consortium uses RNAi to uncover genes' function. Lancet. 361:2003;584.
204. Baylin S.B. Mechanisms underlying epigenetically mediated gene silencing in cancer. Cancer Biol. 12:2002;331-337.
205. Couzin J. Mini RNA molecules shield mouse liver from hepatitis. Science. 299:2003;995.
206. Hwu P. Gene therapy. In: DeVita Jr VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. 6th ed. Philadelphia: Lippincott, Williams and Wilkins; 2001, chapter 62-1. p. 3161-76.
207. Westphal E.M., von Melchner H. Gene therapy approaches for the selective killing of cancer cells. Curr. Pharm. Dis. 8:2002;1683-1694.
208. Reed J.C. Apoptosis-based therapies. Nat. Rev. Drug. Discov. 1:2002;111-121.
209. Rosenberg S.A. Cellular therapy: an introduction. Cancer J. 7(Suppl 2):2001;S51-S52.
210. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.Y., Hwu P., Schwartzentruber J.et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:2002;850-854.
211. Riddell S.R., Greenberg P.D. Principles for adoptive T cell therapy of human viral diseases. Annu. Rev. Immunol. 13:1995;545-586.
212. Gupta S., Kanodia A.K. Biological response modifiers in cancer therapy. Nat. Med. J. India. 15:2002;202-207.
213. Galun E., Axelrod J.H. The role of cytokines in liver failure and regeneration: potential new molecular therapies. Biochim. Biophys. Acta. 1592:2002;345-358.
214. Sangro B., Herraiz M., Prieto J. Gene therapy of neoplastic liver diseases. Int. J. Biochem. Cell Biol. 35:2003;135-148.
215. Simkiss D. Hepatitis B immunization. J. Trop. Pediatr. 48:2002;256-257.